Invention, Innovation, and Commercialisation in British Biophysics
Abstract
British biophysics has a rich tradition of scientific invention and innovation, on several occasions resulting in new technologies which have transformed biological insight, such as rapid DNA sequencing, high-precision super-resolution and label-free microscopy hardware, new approaches for high-throughput and single-molecule bio-sensing, and the development of a range of de novo bio-inspired synthetic materials. Some of these advances have been established through democratised, open-source platforms and many have biomedical success, a key example involving the SARS-CoV-2 spike protein during the COVID-19 pandemic. Here, three UK labs made crucial contributions in revealing how the spike protein targets human cells, and how therapies such as vaccines and neutralizing nanobodies likely work, enabled in large part through the biophysical technological innovations of cryo-electron microscopy. In this review, we discuss leading-edge technological and methodological innovations which resulted from initial outcomes of discovery-led 'Physics of Life' (PoL) research (capturing biophysics, biological physics and multiple blends of physical-life sciences interdisciplinary research in the UK) and which have matured into wider-reaching sustainable commercial ventures enabling significant translational impact. We describe the fundamental biophysical science which led to a diverse range of academic spinouts, presenting the scientific questions that were first asked and addressed through innovating new techniques and approaches, and highlighting the key publications which ultimately led to commercialisation. We consider these example companies through the lens of opportunities and challenges for academic biophysics research in partnership with British industry. Finally, we propose recommendations concerning future resourcing and structuring of UK biophysics research and the training and support of...